CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Zydus Cadila seeks phase III approval; drops after a strong opening
Deepti Shidore
/ Categories: Trending, DSIJ News

Zydus Cadila seeks phase III approval; drops after a strong opening

After approving Sputnik-V from Dr Reddy’s Lab and Covaxin from Bharat Biotech, ZyCoV-D is the next one in line seeking permission to start phase III trials.  

 

Zydus Cadila, a global pharmaceutical company that discovers & develops NCEs, biosimilars and vaccines, is ready to initiate planning with 30,000 volunteers.   

 

Data & Safety Monitoring Board (DSMB) reviewed the trial and further reported to Central Drugs Standard Control Organisation (CDSCO) for an update on the safety outcome.   

 

Commenting on this progress, Chairman of Zydus Group said, “After establishing safety in phase I clinical trial, ZyCoV-D has now completed phase II clinical trials and the vaccine has been found to be safe and immunogenic. We are optimistic of phase III clinical trial outcomes as well and that we would be able to start the production of the novel vaccine on its successful completion.”  

 

The spike protein of SARS-CoV-2 is one of the more-preferred vaccine targets and is being used in Sputnik-V and NVX-CoV2373 as well. ZyCoV-D has created a DNA vaccine platform, where once the plasma DNA is introduced to the host cells, it gets translated into the viral protein which will elicit a strong immune response that protects from diseases and aids the human body to fights viruses.  

 

Cadila stock opened at Rs 496 per share, 7 points higher from its previous close. Despite the announcement, we saw profit booking today. As a result, the stock dropped and is now at Rs 488.45 per share. 

Previous Article Bharat Forge invests in Avaada SataraMH for purchase of solar power; stock trades flat
Next Article Why is there net-outflow from equity MF?
Print
690 Rate this article:
4.3
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR